News
-
09.04.2021Successful initial public offering of Captor Therapeutics S.A.morethe largest ever biotechnology company public offering on the Warsaw Stock Exchange
-
23.03.2021Captor Therapeutics S.A. rozpoczyna ofertę publiczną akcji (IPO)moreSpółka opublikowała 22 marca 2021 r. prospekt sporządzony w związku z ofertą publiczną
-
15.03.2021Captor Therapeutics S.A. is set to conduct a public offeringmoreand list its shares on the Warsaw Stock Exchange
-
01.03.2021Paweł Dobrzański, PhD, joins Captor Therapeutics S.A. as Biology Department DirectormorePawel Dobrzański, an international expert in molecular biology and drug development, will support our team!
-
20.01.2021Tom Shepherd as Chief Executive OfficermoreCaptor Therapeutics S.A. announces the appointment of Tom Shepherd, Ph.D., as Chief Executive Officer
-
22.12.2020Captor Therapeutics and Sosei Heptares Enter Strategic CollaborationmoreFocused on Targeted GPCR Degradation as Novel Approach for Drug Design
-
22.10.2020Captor Therapeutics as one of the „Scrip’s 10 To Watch”moreWe have been selected as one of the „Scrip’s 10 To Watch” companies at #BIOEurope Digital 2020!
-
24.04.2020A new project in the area of autoimmune diseasesmoreWe have received over 27 M PLN grant for a new project!
-
05.03.2020Advancing the technological platformmoreA new grant will support...
-
21.02.2020Captor's review articlemoreOur review on protein degradation technology has been published in "Technology Transfer and Entrepreneurship"...